| [1] |
Abraha I, Cruz-Jentoft A, Soiza RL, et al. Evidence of and recommendations for non-pharmacological interventions for common geriatric conditions: the SENATOR-ONTOP systematic review protocol[J].BMJ Open, 2015, 5(1): e007488.
|
| [2] |
Onder G, Landi F, Fusco D, et al. Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate medication use among elderly complex patients (CRIME) project [J]. Drugs Aging, 2014, 31(1): 33-45.
|
| [3] |
Chan M, Tsuyuki R. Heart failure in the elderly[J]. Curr Opin Cardiol, 2013, 28(2): 234-241.
|
| [4] |
Vetrano DL, Lattanzio F, Martone AM, et al. Treating heart failure in older and oldest old patients[J]. Curr Pharm Des, 2015, 21(13): 1659-1664.
|
| [5] |
Khan H, Kalogeropoulos AP, Georgiopoulou VV, et al. Frailty and risk for heart failure in older adults: the health, aging, and body composition study[J].Am Heart J, 2013, 166(5): 887-894.
|
| [6] |
洪华山.慢性老年心力衰竭药物与非药物治疗现状[J].中华老年心脑血管病杂志, 2015, 17(8): 785-788.
|
| [7] |
董碧蓉，李小鹰.老年患者衰弱评估及干预中国专家共识[J].中华老年医学杂志, 2017, 36(3): 251-256.
|
| [8] |
Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty[J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3): M158-166.
|
| [9] |
Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study[J]. J Am Geriatr Soc, 2005, 53(8): 1321-1330.
|
| [10] |
Denfeld QE, Winters-Stone K, Mudd JO, et al. The prevalence of frailty in heart failure: a systematic review and meta-analysis[J]. Int J Cardiol, 2017, 236: 283-289.
|
| [11] |
Pulignano G, Del Sindaco D, Di Lenarda A, et al. Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a costeffectiveness, pilot study[J]. J Cardiovasc Med, 2010, 11: 739-747.
|
| [12] |
Murad K, Kitzman DW. Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management[J]. Heart Fail Rev, 2012, 17(4-5): 581-588.
|
| [13] |
Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly[J]. Arch Intern Med, 2002, 162(20): 2269-2276.
|
| [14] |
Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure[J]. J Am Coll Cardiol, 2003, 42(7): 1226-1233.
|
| [15] |
Vetrano DL, Lattanzio F, Martone AM, et al. Treating heart failure in older and oldest old patients[J]. Curr Pharm Des, 2015, 21(13): 1659-1664.
|
| [16] |
Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction[J]. N Engl J Med, 2008, 359(23): 2456-2467.
|
| [17] |
Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial[J]. Lancet, 2003, 362(9386): 777-781.
|
| [18] |
DjousséL, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure[J]. JAMA, 2009, 302(4): 394-400.
|
| [19] |
Larsson SC, Tektonidis TG, Gigante B, et al. Healthy lifestyle and risk of heart failure: results from 2 prospective cohort studies[J]. Circ Heart Fail, 2016, 9(4): e002855.
|
| [20] |
Danelich IM, Reed BN, Sueta CA1. Stage A: can heart failure be prevented[J]?Curr Cardiol Rev, 2015, 11(1): 4-9.
|
| [21] |
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8): 891-975.
|
| [22] |
Yancy CW, Jessup M, Bozkurt B, et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure cociety of America[J].Circulation, 2017, 136(6): e137-e161.
|
| [23] |
Go AS, Yang J, Gurwitz JH, et al. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice[J].Arch Intern Med, 2008, 168(22): 2415-2421.
|
| [24] |
Kramer JM, Curtis LH, Dupree CS, et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure[J]. Arch Intern Med, 2008, 168(22): 2422-2432.
|
| [25] |
van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)[J]. J Am Coll Cardiol, 2009, 53(23): 2150-2158.
|
| [26] |
Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo controlled study[J]. Lancet, 2010, 376(9744): 875-885.
|
| [27] |
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004.
|
| [28] |
Abete P, Testa G, Della-Morte D, et al. Treatment for chronic heart failure in the elderly: current practice and problems[J].Heart Fail Rev, 2013, 18(4): 529-551.
|
| [29] |
Tehrani F, Phan A, Chien CV, et al. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction[J]. Am J Cardiol, 2009, 103(6): 829-833.
|